BNP Paribas Financial Markets
RLMD icon

BNP Paribas Financial Markets’s Relmada Therapeutics RLMD Stock Holding History

BNP Paribas Financial Markets’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.8K Buy
14,429
+6,109
+73% +$42.7K ﹤0.01% 4553
2026
Q1 		$57.9K Buy
8,320
+5,280
+174% +$25K ﹤0.01% 4617
2025
Q4 		$14.7K Buy
3,040
+2,947
+3,169% +$9.87K ﹤0.01% 5086
2025
Q3 		$187 Buy
93
+6
+7% +$6 ﹤0.01% 5396
2025
Q2 		$52 Buy
87
+15
+21% +$8 ﹤0.01% 5352
2025
Q1 		$19 Hold
72
– – ﹤0.01% 5323
2024
Q4 		$37 Buy
+72
New +$176 ﹤0.01% 5328

Other funds holding RLMD

JTL
Jupiter Topco LLC New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BNP Paribas Financial Markets's RLMD Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Relmada Therapeutics (RLMD) stake by 73% in Q2 2026, buying an estimated $42.7K and bringing the position to 14,429 shares worth $99.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4553.

BNP Paribas Financial Markets first reported a position in RLMD in Q4 2024 and has held it in 7 quarters since. 115 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • BNP Paribas Financial Markets held 14,429 shares of Relmada Therapeutics worth $99.8K as of Q2 2026.
  • BNP Paribas Financial Markets bought 6,109 Relmada Therapeutics shares in Q2 2026, an estimated $42.7K.
  • Relmada Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4553 holding.
  • BNP Paribas Financial Markets first reported a position in Relmada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 115 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.